PT  - JOURNAL ARTICLE
AU  - Riaz Mahmud
AU  - H. M. Abrar Fahim Patwari
TI  - Estimation of the Basic Reproduction Number of SARS-CoV-2 in Bangladesh Using Exponential Growth Method
AID  - 10.1101/2020.09.29.20203885
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.29.20203885
4099  - http://medrxiv.org/content/early/2020/09/30/2020.09.29.20203885.short
4100  - http://medrxiv.org/content/early/2020/09/30/2020.09.29.20203885.full
AB  - Objectives In December 2019, a novel coronavirus (SARS-CoV-2) outbreak emerged in Wuhan, Hubei Province, China. Soon, it has spread out across the world and become an ongoing pandemic. In Bangladesh, the first case of novel coronavirus (SARS-CoV-2) was detected on March 8, 2020. Since then, not many significant studies have been conducted to understand the transmission dynamics of novel coronavirus (SARS-CoV-2) in Bangladesh. In this study, we estimated the basic reproduction number R0 of novel coronavirus (SARS-CoV-2) in Bangladesh.Methods The data of daily confirmed cases of novel coronavirus (SARS-CoV-2) in Bangladesh and the reported values of generation time of novel coronavirus (SARS-CoV-2) for Singapore and Tianjin, China, were collected. We calculated the basic reproduction number R0 by applying the exponential growth (EG) method. Epidemic data of the first 76 days and different values of generation time were used for the calculation.Results The basic reproduction number R0 of novel coronavirus (SARS-CoV-2) in Bangladesh is estimated to be 2.66 [95% CI: 2.58-2.75], optimized R0 is 2.78 [95% CI: 2.69-2.88] using generation time 5.20 with a standard deviation of 1.72 for Singapore. Using generation time 3.95 with a standard deviation of 1.51 for Tianjin, China, R0 is estimated to be 2.15 [95% CI: 2.09-2.20], optimized R0 is 2.22 [95% CI: 2.16-2.29].Conclusions The calculated basic reproduction number R0 of novel coronavirus (SARS-CoV-2) in Bangladesh is significantly higher than 1, which indicates its high transmissibility and contagiousness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In this study, the data were collected from publicly available resources. Hence, ethics statement is not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn this study, the data were collected from publicly available resources. https://ourworldindata.org/coronavirus-source-data https://www.worldometers.info/coronavirus/